UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma

Journal of allergy and clinical immunology, 2013-03, Vol.131 (3), p.866-874

2013

Volltextzugriff (PDF)

Impact of guideline awareness on the counseling of patients with acute cough among general practitioners and pharmacy personnel

PloS one, 2021-08, Vol.16 (8), p.e0254086

2021

Volltextzugriff (PDF)

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

Respiratory medicine, 2014-04, Vol.108 (4), p.584-592

2014

Volltextzugriff (PDF)

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

Pulmonary pharmacology & therapeutics, 2015-06, Vol.32, p.53-59

2015

Volltextzugriff (PDF)

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial

International journal of chronic obstructive pulmonary disease, 2024-01, Vol.19, p.205-216

2024

Volltextzugriff (PDF)

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis

Respiratory research, 2018-01, Vol.19 (1), p.18-18, Article 18

2018

Volltextzugriff (PDF)

Pulmonary Therapy: Looking Back on 2018 and Forward to 2019

Pulmonary therapy, 2019-06, Vol.5 (1), p.1-3

Beeh, Kai-Michael

2019

Volltextzugriff (PDF)

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice

ERJ open research, 2021-04, Vol.7 (2), p.950

2021

Volltextzugriff (PDF)

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

Respiratory research, 2015-07, Vol.16 (1), p.87-87, Article 87

2015

Volltextzugriff (PDF)

Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations

BMC pharmacology & toxicology, 2018-07, Vol.19 (1), p.40-40, Article 40

2018

Volltextzugriff (PDF)

Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?

Lung cancer (Amsterdam, Netherlands), 2002-09, Vol.37 (3), p.271-276

2002

Volltextzugriff (PDF)

Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium

Respiratory research, 2012-06, Vol.13 (1), p.52-52

2012

Volltextzugriff (PDF)

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

Respiratory research, 2014-06, Vol.15 (1), p.61-61

2014

Volltextzugriff (PDF)

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)

International journal of chronic obstructive pulmonary disease, 2016-02, Vol.11, p.193-205

2016

Volltextzugriff (PDF)

Improvement in quality of life with omalizumab in patients with severe allergic asthma

Current medical research and opinion, 2006-11, Vol.22 (11), p.2201-2208

2006

Volltextzugriff (PDF)

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

Respiratory research, 2019-08, Vol.20 (1), p.180-180, Article 180

2019

Volltextzugriff (PDF)

COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type‐2 and PDE4 gene expression in sputum

Journal of cellular and molecular medicine, 2021-01, Vol.25 (2), p.905-918

2021

Volltextzugriff (PDF)

CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD

Respiratory research, 2024-10, Vol.25 (1), p.380-13, Article 380

2024

Volltextzugriff (PDF)

Pulmonary Therapy 2020 Update and Podcast: Meet the Journal’s Editors-in-Chief

Pulmonary therapy, 2020-06, Vol.6 (1), p.1-7

2020

Volltextzugriff (PDF)

Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis

Respiratory research, 2020-03, Vol.21 (1), p.72-72, Article 72

2020

Volltextzugriff (PDF)

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial

International journal of chronic obstructive pulmonary disease, 2021-01, Vol.16, p.79-89

2021

Volltextzugriff (PDF)

Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany

International journal of chronic obstructive pulmonary disease, 2024-01, Vol.19, p.945-956

2024

Volltextzugriff (PDF)

Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD

Chronic obstructive pulmonary disease, 2011-10, Vol.8 (5), p.340-345

2011

Volltextzugriff (PDF)

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

BMC pulmonary medicine, 2014-01, Vol.14 (1), p.4-4, Article 4

2014

Volltextzugriff (PDF)

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat ® in Asthma Using Standardized Sample-Contamination Avoidance

Journal of aerosol medicine and pulmonary drug delivery, 2016-10, Vol.29 (5), p.406-415

2016

Volltextzugriff (PDF)

1 – 25 von 78

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(73)

Publikationsform

Artikel
(77)
Dissertationen
(1)

Sprache

Englisch
(73)
Deutsch
(5)

Erscheinungsjahr

n.n

Thema

Science & Technology
(54)
Life Sciences & Biomedicine
(53)
Humans
(46)
Respiratory System
(38)
Male
(36)
Middle Aged
(33)
Female
(32)
Aged
(27)
Pulmonary Disease, Chronic Obstructive - Drug Therapy
(25)
Adult
(24)
Asthma
(21)
Biological And Medical Sciences
(21)
Medical Sciences
(21)
Chronic Obstructive Pulmonary Disease
(19)
Copd
(19)
Treatment Outcome
(19)
Double-Blind Method
(18)
Cross-Over Studies
(16)
Administration, Inhalation
(13)
Pneumology
(13)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent allergic asthma

Impact of guideline awareness on the counseling of patients with acute cough among general practitioners and pharmacy personnel

Effect of QVA149 on lung volumes and exercise tolerance in COPD patients: The BRIGHT study

The 24-h lung-function profile of once-daily tiotropium and olodaterol fixed-dose combination in chronic obstructive pulmonary disease

Real-World Effectiveness of Fluticasone Furoate/Umeclidinium/Vilanterol Once-Daily Single-Inhaler Triple Therapy for Symptomatic COPD: The ELLITHE Non-Interventional Trial

Long-acting bronchodilators improve exercise capacity in COPD patients: a systematic review and meta-analysis

Pulmonary Therapy: Looking Back on 2018 and Forward to 2019

INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual clinical practice

Randomised, double-blind, placebo-controlled crossover study to investigate different dosing regimens of olodaterol delivered via Respimat® in patients with moderate to severe persistent asthma

Characterization of differential patient profiles and therapeutic responses of pharmacy customers for four ambroxol formulations

Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer—what limits limited disease?

Clinical trial design in chronic obstructive pulmonary disease: current perspectives and considerations with regard to blinding of tiotropium

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma

The lung function profile of once-daily tiotropium and olodaterol via Respimat® is superior to that of twice-daily salmeterol and fluticasone propionate via Accuhaler® (ENERGITO® study)

Improvement in quality of life with omalizumab in patients with severe allergic asthma

Effect of the inhaled PDE4 inhibitor CHF6001 on biomarkers of inflammation in COPD

COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type‐2 and PDE4 gene expression in sputum

CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD

Pulmonary Therapy 2020 Update and Podcast: Meet the Journal’s Editors-in-Chief

Sputum and blood transcriptomics characterisation of the inhaled PDE4 inhibitor CHF6001 on top of triple therapy in patients with chronic bronchitis

Comparison of Dry-Powder Inhaler and Pressurized Metered-Dose Inhaler Formulations of Extrafine Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrronium in Patients with COPD: The TRI-D Randomized Controlled Trial

Characteristics of Users and New Initiators of Single- and Multiple-Inhaler Triple Therapy for Chronic Obstructive Pulmonary Disease in Germany

Effect of Indacaterol on Dynamic Lung Hyperinflation and Breathlessness in Hyperinflated Patients with COPD

A blinded evaluation of the efficacy and safety of glycopyrronium, a once-daily long-acting muscarinic antagonist, versus tiotropium, in patients with COPD: the GLOW5 study

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat ® in Asthma Using Standardized Sample-Contamination Avoidance

Suchergebnisse filtern